Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Celerion Expands Belfast Facility with Containment Room to Enable Live Biologics and Vaccine Studies

Celerion Expands Belfast Facility with Containment Room to Enable Live Biologics and Vaccine Studies.

(Lincoln, NE; June 5, 2013)Celerion announces the addition of a Containment Room at the Belfast, Northern Ireland UK facility. The new Containment Room will allow Celerion to develop programs that require studies utilizing biologics, as well as vaccines with primary and secondary containment.

The Containment Room is a modular facility comprising a negative pressure processing room which houses a Biosafety Level (BSL-2) cabinet. The addition of the Containment Room further enhances the current GMP licensed site by enabling the processing of live class 2 and class 3 biological products.

“The addition of the Containment Room, coupled with our ability in the Belfast clinic to recruit large numbers of study participants, places Celerion in a strong position to conduct studies requiring biologics and vaccines,“ said Phil Bach, Vice President of Global Clinical Research at Celerion. “Celerion’s facility in Belfast continues to go from strength to strength. This announcement builds on the recent addition of the Bronchoscopy Suite and expansion of our services in the respiratory therapeutic area. The Belfast clinic is widely recognized as the Respiratory Centre of Excellence with experience in asthma, COPD, cystic fibrosis, and bronchiectasis clinical research.”

Celerion’s facility in Belfast, Northern Ireland, UK also has extensive early stage clinical capabilities based on First-In-Human experience with both NCEs and biologics, as well as bioequivalence, biosimilars, obesity, ophthalmic and gastro-intestinal studies.

About Celerion
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.

With over 40 years of experience and 750 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiac safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. For more information please visit

Media Contact:

Farzana Azam
Executive Director, Global Marketing